Long-term anticoagulation for adults with severe hemophilia A
Report of a Clinical-biological Case: "Long-term Anticoagulation in a Patient With Severe Hemophilia A
This project will see if adults with severe hemophilia A who are on modern factor VIII prophylaxis can be safely treated with long-term blood thinners.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT07314983 on ClinicalTrials.gov |
What this trial studies
This observational project will collect clinical data from adult patients with severe hemophilia A who receive long-term anticoagulation while on modern factor VIII prophylaxis, including extended half-life products. Researchers will document the type and dose of anticoagulant, details of FVIII replacement, bleeding and thrombotic events, and other clinical outcomes. No interventional treatment will be assigned — the work uses routine care and medical records, with inclusion dependent on absence of objection to data reuse. All cases are being gathered at the Hemostasis Unit, CHU de Strasbourg, creating a focused single-center case series to inform safety and management strategies.
Who should consider this trial
Good fit: Ideal candidates are adults (≥18) with severe hemophilia A (FVIII <1%) who are receiving or expected to require long-term anticoagulation and who have not objected to reuse of their medical data.
Not a fit: People unlikely to benefit include children, those with mild or moderate hemophilia A, patients who never receive anticoagulation, and individuals who have refused reuse of their records.
Why it matters
Potential benefit: If successful, this work could help doctors decide when and how to give long-term anticoagulants to people with severe hemophilia A who are on modern FVIII prophylaxis.
How similar studies have performed: This is largely novel — the investigators note no published cases of long-term anticoagulation in severe hemophilia A, though short-term anticoagulation and reports in milder hemophilia have been described.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥ 18 years) with severe hemophilia A * Absence of written objection in the subject's medical record to the reuse of their data for scientific research purposes. Exclusion Criteria: \- Subject having expressed objection to the reuse of their data for scientific research
Where this trial is running
Strasbourg
- Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Laurent SATTLER, PharmD
- Email: laurent.sattler@chru-strasbourg.fr
- Phone: 33 3 88 12 75 28
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.